The April order rescheduling DEA-approved medications and state-licensed medical marijuana to Schedule III set off a scramble in the capital markets. Two questions sit at the center of it: Can plant-touching companies finally list on the major U.S. stock exchanges, and will banks finally open their doors to the industry? On the first question, the








